Difference between revisions of "Breast cancer, CNS metastases"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "_99|" to "_999|") |
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
||
Line 24: | Line 24: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/ | + | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/study/NCT02915744 Clinical Trial Registry] |
==Eribulin monotherapy {{#subobject:ef2415|Regimen=1}}== | ==Eribulin monotherapy {{#subobject:ef2415|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 48: | Line 48: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/ | + | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/study/NCT02915744 Clinical Trial Registry] |
==Gemcitabine monotherapy {{#subobject:af0915|Regimen=1}}== | ==Gemcitabine monotherapy {{#subobject:af0915|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/ | + | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/study/NCT02915744 Clinical Trial Registry] |
==Ixabepilone monotherapy {{#subobject:9df286|Regimen=1}}== | ==Ixabepilone monotherapy {{#subobject:9df286|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 77: | Line 77: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/ | + | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/study/NCT02915744 Clinical Trial Registry] |
==Paclitaxel monotherapy, weekly {{#subobject:b55e07|Regimen=1}}== | ==Paclitaxel monotherapy, weekly {{#subobject:b55e07|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/ | + | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/study/NCT02915744 Clinical Trial Registry] |
==nab-Paclitaxel monotherapy {{#subobject:7592da|Regimen=1}}== | ==nab-Paclitaxel monotherapy {{#subobject:7592da|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/ | + | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/study/NCT02915744 Clinical Trial Registry] |
==Vinorelbine monotherapy {{#subobject:5c104c|Regimen=1}}== | ==Vinorelbine monotherapy {{#subobject:5c104c|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/ | + | # '''ATTAIN:''' Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. [https://doi.org/10.1001/jamaoncol.2022.0514 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100460/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35552364/ PubMed] [https://clinicaltrials.gov/study/NCT02915744 Clinical Trial Registry] |
=HER2-positive, first-line therapy= | =HER2-positive, first-line therapy= | ||
==Capecitabine & Lapatinib {{#subobject:800fde|Regimen=1}}== | ==Capecitabine & Lapatinib {{#subobject:800fde|Regimen=1}}== | ||
Line 124: | Line 124: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [https://doi.org/10.1200/JCO.2014.57.1794 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25605838/ PubMed] [https://clinicaltrials.gov/ | + | #'''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [https://doi.org/10.1200/JCO.2014.57.1794 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25605838/ PubMed] [https://clinicaltrials.gov/study/NCT00820222 Clinical Trial Registry] |
==Capecitabine & Trastuzumab (XH) {{#subobject:677608|Regimen=1}}== | ==Capecitabine & Trastuzumab (XH) {{#subobject:677608|Regimen=1}}== | ||
XH: '''<u>X</u>'''eloda (Capecitabine) & '''<u>H</u>'''erceptin | XH: '''<u>X</u>'''eloda (Capecitabine) & '''<u>H</u>'''erceptin | ||
Line 158: | Line 158: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [https://doi.org/10.1200/JCO.2014.57.1794 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25605838/ PubMed] [https://clinicaltrials.gov/ | + | #'''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [https://doi.org/10.1200/JCO.2014.57.1794 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25605838/ PubMed] [https://clinicaltrials.gov/study/NCT00820222 Clinical Trial Registry] |
=HER2-positive, subsequent lines of therapy= | =HER2-positive, subsequent lines of therapy= | ||
Line 191: | Line 191: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [https://doi.org/10.1200/JCO.2014.57.1794 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25605838/ PubMed] [https://clinicaltrials.gov/ | + | #'''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [https://doi.org/10.1200/JCO.2014.57.1794 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25605838/ PubMed] [https://clinicaltrials.gov/study/NCT00820222 Clinical Trial Registry] |
==Capecitabine & Trastuzumab (XH) {{#subobject:677608|Regimen=1}}== | ==Capecitabine & Trastuzumab (XH) {{#subobject:677608|Regimen=1}}== | ||
XH: '''<u>X</u>'''eloda (Capecitabine) & '''<u>H</u>'''erceptin | XH: '''<u>X</u>'''eloda (Capecitabine) & '''<u>H</u>'''erceptin | ||
Line 225: | Line 225: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [https://doi.org/10.1200/JCO.2014.57.1794 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25605838/ PubMed] [https://clinicaltrials.gov/ | + | #'''CEREBEL:''' Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. [https://doi.org/10.1200/JCO.2014.57.1794 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/25605838/ PubMed] [https://clinicaltrials.gov/study/NCT00820222 Clinical Trial Registry] |
==Capecitabine & Trastuzumab (XH) & Tucatinib {{#subobject:8d0gg5|Regimen=1}}== | ==Capecitabine & Trastuzumab (XH) & Tucatinib {{#subobject:8d0gg5|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 254: | Line 254: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # '''HER2CLIMB:''' Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):597-609. Epub 2019 Dec 11. Erratum in: N Engl J Med. 2020 Feb 6;382(6):586. [https://doi.org/10.1056/nejmoa1914609 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31825569/ PubMed] [https://clinicaltrials.gov/ | + | # '''HER2CLIMB:''' Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):597-609. Epub 2019 Dec 11. Erratum in: N Engl J Med. 2020 Feb 6;382(6):586. [https://doi.org/10.1056/nejmoa1914609 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31825569/ PubMed] [https://clinicaltrials.gov/study/NCT02614794 Clinical Trial Registry] |
## '''Subgroup analysis:''' Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020 Aug 10;38(23):2610-2619. Epub 2020 May 29. [https://doi.org/10.1200/jco.20.00775 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403000/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32468955/ PubMed] | ## '''Subgroup analysis:''' Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020 Aug 10;38(23):2610-2619. Epub 2020 May 29. [https://doi.org/10.1200/jco.20.00775 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403000/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32468955/ PubMed] | ||
Revision as of 01:35, 25 June 2023
11 regimens on this page
6 variants on this page
|
Note: these are studies of regimens tested in patients with breast cancer and CNS metastases, or subgroups of more general studies that focused on patients with CNS metastases. Please see the main breast cancer page for other regimens.
Guidelines
ASCO
- 2022: Ramakrishna et al. Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
Older
- 2018: Ramakrishna et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline update PubMed
- 2014: Ramakrishna et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline PubMed
Unselected, all lines of therapy
Docetaxel monotherapy
D: Docetaxel
T: Taxotere (Docetaxel)
References
- ATTAIN: Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. link to original article link to PMC article PubMed Clinical Trial Registry
Eribulin monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Tripathy et al. 2022 (ATTAIN) | 2017-2019 | Phase 3 (C) | Etirinotecan pegol | Did not meet primary endpoint of OS |
Chemotherapy
- Eribulin (Halaven) 1.4 mg/m2 IV over 2 to 5 minutes once per day on days 1 & 8
21-day cycles
References
- ATTAIN: Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. link to original article link to PMC article PubMed Clinical Trial Registry
Gemcitabine monotherapy
References
- ATTAIN: Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. link to original article link to PMC article PubMed Clinical Trial Registry
Ixabepilone monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Tripathy et al. 2022 (ATTAIN) | 2017-2019 | Phase 3 (C) | Etirinotecan pegol | Did not meet primary endpoint of OS |
References
- ATTAIN: Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. link to original article link to PMC article PubMed Clinical Trial Registry
Paclitaxel monotherapy, weekly
References
- ATTAIN: Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. link to original article link to PMC article PubMed Clinical Trial Registry
nab-Paclitaxel monotherapy
References
- ATTAIN: Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. link to original article link to PMC article PubMed Clinical Trial Registry
Vinorelbine monotherapy
References
- ATTAIN: Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, Cortés J; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncol. 2022 Jul 1;8(7):1047-1052. link to original article link to PMC article PubMed Clinical Trial Registry
HER2-positive, first-line therapy
Capecitabine & Lapatinib
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Pivot et al. 2015 (CEREBEL) | 2009-2012 | Phase 3 (E-switch-ic) | Capecitabine & Trastuzumab | Did not meet primary endpoint of CNS metastases as first site of relapse |
Biomarker eligibility criteria
- Gene: HER2 Positive
- Clinical Trial Eligibility: score > 2.2 by fluorescence in situ hybridization and/or 3+ amplification by immunohistochemistry or chromogenic/silver in situ hybridization
Chemotherapy
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
Targeted therapy
- Lapatinib (Tykerb) 1250 mg PO once per day
21-day cycles
References
- CEREBEL: Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. link to original article PubMed Clinical Trial Registry
Capecitabine & Trastuzumab (XH)
XH: Xeloda (Capecitabine) & Herceptin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Pivot et al. 2015 (CEREBEL) | 2009-2012 | Phase 3 (C) | Capecitabine & Lapatanib | Did not meet primary endpoint of CNS metastases as first site of relapse |
Biomarker eligibility criteria
- Gene HER2 Positive
- Clinical Trial Eligibility: score > 2.2 by fluorescence in situ hybridization and/or 3+ amplification by immunohistochemistry or chromogenic/silver in situ hybridization
Chemotherapy
- Capecitabine (Xeloda) 1250 mg/m2 PO twice per day on days 1 to 14
Targeted therapy
- Trastuzumab (Herceptin) as follows:
- Cycle 1: 8 mg/kg IV once on day 1
- Cycle 2 onwards: 6 mg/kg IV once on day 1
21-day cycles
References
- CEREBEL: Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. link to original article contains dosing details in abstract PubMed Clinical Trial Registry
HER2-positive, subsequent lines of therapy
Capecitabine & Lapatinib
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Pivot et al. 2015 (CEREBEL) | 2009-2012 | Phase 3 (E-switch-ic) | Capecitabine & Trastuzumab | Did not meet primary endpoint of CNS metastases as first site of relapse |
Biomarker eligibility criteria
- Gene: HER2 Positive
- Clinical Trial Eligibility: score > 2.2 by fluorescence in situ hybridization and/or 3+ amplification by immunohistochemistry or chromogenic/silver in situ hybridization
Chemotherapy
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
Targeted therapy
- Lapatinib (Tykerb) 1250 mg PO once per day
21-day cycles
References
- CEREBEL: Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. link to original article PubMed Clinical Trial Registry
Capecitabine & Trastuzumab (XH)
XH: Xeloda (Capecitabine) & Herceptin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Pivot et al. 2015 (CEREBEL) | 2009-2012 | Phase 3 (C) | Capecitabine & Lapatanib | Did not meet primary endpoint of CNS metastases as first site of relapse |
Biomarker eligibility criteria
- Gene HER2 Positive
- Clinical Trial Eligibility: score > 2.2 by fluorescence in situ hybridization and/or 3+ amplification by immunohistochemistry or chromogenic/silver in situ hybridization
Chemotherapy
- Capecitabine (Xeloda) 1250 mg/m2 PO twice per day on days 1 to 14
Targeted therapy
- Trastuzumab (Herceptin) as follows:
- Cycle 1: 8 mg/kg IV once on day 1
- Cycle 2 onwards: 6 mg/kg IV once on day 1
21-day cycles
References
- CEREBEL: Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. Epub 2015 Jan 20. link to original article contains dosing details in abstract PubMed Clinical Trial Registry
Capecitabine & Trastuzumab (XH) & Tucatinib
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Murthy et al. 2019 (HER2CLIMB) | 2016-2019 | Phase 3 (E-RT-esc) | XH | Superior OS (secondary endpoint) Median OS: 21.9 vs 17.4 mo (HR 0.66, 95% CI 0.50-0.88) |
Chemotherapy
- Capecitabine (Xeloda) 1000 mg/m2 PO twice per day on days 1 to 14
Targeted therapy
- Tucatinib (Tukysa) 300 mg PO twice per day
- Trastuzumab (Herceptin) as follows:
- Cycle 1: 8 mg/kg IV once on day 1
- Cycle 2 onwards: 6 mg/kg IV once on day 1
21-day cycles
References
- HER2CLIMB: Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 Feb 13;382(7):597-609. Epub 2019 Dec 11. Erratum in: N Engl J Med. 2020 Feb 6;382(6):586. link to original article contains dosing details in manuscript PubMed Clinical Trial Registry
- Subgroup analysis: Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020 Aug 10;38(23):2610-2619. Epub 2020 May 29. link to original article link to PMC article PubMed